Key result
Clonally derived cell lines expressing ribozymes delivered by the LNL6 retroviral vector showed inhibition of Moloney murine leukaemia virus replication.
Ribozymes delivered via a retroviral vector can selectively cleave viral RNA and inhibit Moloney murine leukaemia virus replication in vitro.
Provides in vitro proof-of-concept for ribozyme vectors; leaves open translation to animal models or clinical use.
The packaging region psi is the RNA sequence which directs the inclusion of genomic viral RNA into virions. As such it represents an apparently accessible site for ribozyme action. Ribozymes directed against the psi site of Moloney murine leukaemia virus (MoMLV) were delivered to target cells using a related retroviral vector, LNL6. LNL6 is a vector predominantly derived from MoMLV and, like all retroviruses, requires the psi region to be packaged. By exploiting the heterogeneity between nucleotide sequences of the MoMLV target and LNL6 vector in the psi packaging region, two ribozymes were designed and shown to selectively cleave the target but not the vector sequence. Clonally derived cell lines expressing ribozymes showed inhibition of virus replication. These results show the utility of catalytic RNA as specific antiviral agents.
No takes yet. Share an insight, caveat, or question.
Lowenstein et al. (1997) studied Moloney murine leukaemia virus (MoMLV) infection. Retroviral vector LNL6 carrying ribozymes targeted to the psi site was evaluated on Inhibition of virus replication. Clonally derived cell lines expressing ribozymes delivered by the LNL6 retroviral vector showed inhibition of Moloney murine leukaemia virus replication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: